Advanced Tumors Clinical Trial
Official title:
Phase I Clinical Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced malignant tumors.
This trial is an open, dose escalation phase I clinical trial study of patients with advanced
cancer who have failed standard treatment. The trial is divided into a dose escalation phase
and an expansion phase.
Approximately 130 patients will be enrolled in this trial. The dose-increasing phase is about
30 cases, and the expansion stage is about 100 cases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06245122 -
A Study of CS23546 in Subjects With Advanced Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06314087 -
iTAPVR Study - Phase II Randomized Study
|
Phase 2 | |
Recruiting |
NCT05390528 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02419417 -
Study of BMS-986158 in Subjects With Select Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT04808453 -
Phase I Study of CPI-300 in Patients With Advanced Tumors
|
Phase 1 | |
Recruiting |
NCT05799183 -
A SHR-1210 BE Study on Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05429008 -
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
|
Phase 1 | |
Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05213767 -
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04151810 -
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05068856 -
A Study of HRS2543 in Patients With Advanced Tumors
|
Phase 1 | |
Completed |
NCT03781362 -
Study of CPI-100 in Patients With Advanced Tumors
|
Phase 1 | |
Recruiting |
NCT05061628 -
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
|
Phase 1 | |
Recruiting |
NCT05867771 -
A Study of PM1022 in Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03444714 -
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
|
Phase 1 |